Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder DOI Creative Commons

Angela N. Phan,

Garth E. Terry

Frontiers in Psychiatry, Год журнала: 2023, Номер 14

Опубликована: Июнь 26, 2023

Cannabis use disorder (CUD) is prevalent in ~2-5% of adults the United States and anticipated to increase as restrictions cannabis decrease tetrahydrocannabinol (THC) content products increase. No FDA-approved medications for CUD are currently available, despite trials dozens re-purposed novel drugs. Psychedelics have garnered interest a therapeutic class other substance disorders, self-report surveys suggest they may result positive outcomes CUD. Herein, we review existing literature pertaining psychedelic persons with or at risk consider potential rationale underpinning psychedelics treatment CUD.A systematic search was performed several databases. Inclusion criteria were primary research reporting related substances human subjects. Exclusion results including without changes risks associated CUD.Three hundred five unique returned. One article identified using non-classical ketamine CUD; three articles topically relevant based on their secondary data consideration mechanism. Additional reviewed purposes background, safety considerations, formulating rationale.Limited available CUD, more needed given incidence increasing use. While psychedelics, broadly, high index infrequent serious adverse effects, particular effects population, such psychosis cardiovascular events, should be considered. Possible mechanisms by which explored.

Язык: Английский

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial DOI Creative Commons
Jennifer Mitchell,

Marcela Ot’alora G.,

Bessel van der Kolk

и другие.

Nature Medicine, Год журнала: 2023, Номер 29(10), С. 2473 - 2480

Опубликована: Сен. 14, 2023

This multi-site, randomized, double-blind, confirmatory phase 3 study evaluated the efficacy and safety of 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) versus placebo with identical in participants moderate to severe post-traumatic stress disorder (PTSD). Changes Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total severity score (primary endpoint) Sheehan Disability (SDS) functional impairment (key secondary were assessed by blinded independent assessors. Participants randomized MDMA-AT (n = 53) or 51). Overall, 26.9% (28/104) had PTSD, 73.1% (76/104) PTSD. ethnoracially diverse: 28 104 (26.9%) identified as Hispanic/Latino, 35 (33.7%) other than White. Least squares (LS) mean change CAPS-5 (95% confidence interval (CI)) was -23.7 (-26.94, -20.44) -14.8 (-18.28, -11.28) (P < 0.001, d 0.7). LS SDS CI) -3.3 (-4.03, -2.60) -2.1 (-2.89, -1.33) 0.03, 0.4). Seven a treatment emergent adverse event (TEAE) (MDMA-AT, n 5 (9.4%); therapy, 2 (3.9%)). There no deaths serious TEAEs. These data suggest that reduced symptoms diverse population generally well tolerated. ClinicalTrials.gov identifier: NCT04077437 .

Язык: Английский

Процитировано

190
Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis DOI

Yuan Yao,

Dan Guo,

Tangsheng Lu

и другие.

Psychiatry Research, Год журнала: 2024, Номер 335, С. 115886 - 115886

Опубликована: Март 28, 2024

Язык: Английский

Процитировано

25
The integrated treatment of eating disorders, posttraumatic stress disorder, and psychiatric comorbidity: a commentary on the evolution of principles and guidelines DOI Creative Commons
Timothy D. Brewerton

Frontiers in Psychiatry, Год журнала: 2023, Номер 14

Опубликована: Май 12, 2023

Psychiatric comorbidity is the norm in assessment and treatment of eating disorders (EDs), traumatic events lifetime PTSD are often major drivers these challenging complexities. Given that trauma, PTSD, psychiatric significantly influence ED outcomes, it imperative problems be appropriately addressed practice guidelines. The presence associated noted some but not all sets existing guidelines, they mostly do little to address problem other than referring independent guidelines for disorders. This disconnect perpetuates a “silo effect,” which each set complexity comorbidities. Although there several published EDs, likewise, none them specifically + PTSD. result lack integration between providers, leads fragmented, incomplete, uncoordinated ineffective care severely ill patients with situation can inadvertently promote chronicity multimorbidity may particularly relevant treated higher levels care, where prevalence rates concurrent reach as high 50% many more having subthreshold has been progress recognition recommendations treating this common remain undeveloped, when co-occurring disorders, such mood, anxiety, dissociative, substance use, impulse control, obsessive–compulsive, attention-deficit hyperactivity, personality also trauma-related. In commentary, assessing related critically reviewed. An integrated principles used planning trauma-related recommended context intensive therapy. These strategies borrowed from evidence-based approaches. Evidence suggests continuing traditional single-disorder focused, sequential models prioritize integrated, trauma-focused approaches short-sighted perpetuate dangerous multimorbidity. Future would well illness depth.

Язык: Английский

Процитировано

18
Ayahuasca: A review of historical, pharmacological, and therapeutic aspects DOI Creative Commons
Simon Ruffell,

Max Crosland‐Wood,

Rob Palmer

и другие.

Psychiatry and Clinical Neurosciences Reports, Год журнала: 2023, Номер 2(4)

Опубликована: Окт. 2, 2023

Abstract Ayahuasca is a psychedelic plant brew originating from the Amazon rainforest. It formed two basic components, Banisteriopsis caapi vine and containing potent dimethyltryptamine (DMT), usually Psychotria viridis . Here we review history of ayahuasca describe recent work on its pharmacology, phenomenological responses, clinical applications. There has been significant increase in interest since turn millennium. Anecdotal evidence varies significantly, ranging evangelical accounts to horror stories involving physical psychological harm. The effects personality mental health outcomes are discussed this review. Furthermore, analyses experience explored. promising agent that warrants greater empirical attention regarding neurochemical mechanisms action potential therapeutic application.

Язык: Английский

Процитировано

15
Medications for the Treatment of Alcohol Dependence—Current State of Knowledge and Future Perspectives from a Public Health Perspective DOI Open Access
Iga Stokłosa, Gniewko Więckiewicz, Maciej Stokłosa

и другие.

International Journal of Environmental Research and Public Health, Год журнала: 2023, Номер 20(3), С. 1870 - 1870

Опубликована: Янв. 19, 2023

No single effective therapy for alcohol abuse has been found, despite it being a serious sociological and economic problem hundreds of years. It seems difficult to find drug as panacea the due complexity pathophysiology dependence. The purpose this narrative review is existing potentially future pharmaceuticals treatment dependence in most affordable way possible. Psychotherapy mainstay alcoholism, while few drugs approved by legislators are available augmentation treatment, such acamprosate, disulfiram, naltrexone, FDA, nalmefene EMA. There recent reports literature on possibility using baclofen, topiramate, varenicline, gabapentin Moreover, results clinical trials psychoactive substances psilocybin MDMA appear be breakthrough modern abuse. Despite initial optimism, lot scientific effort still needed before new pharmacological methods supporting syndrome will widely available.

Язык: Английский

Процитировано

13
Clinical Effects of Psychedelic Substances Reported to United States Poison Centers: 2012 to 2022 DOI
Mark Simon, Heather Olsen, Christopher Hoyte

и другие.

Annals of Emergency Medicine, Год журнала: 2024, Номер 84(6), С. 605 - 618

Опубликована: Авг. 1, 2024

Язык: Английский

Процитировано

4
Case Report: Well-tolerated MDMA-assisted therapy in a 32-year old female patient with advanced alcohol-induced liver cirrhosis DOI Creative Commons
Monika Kraus,

Stephanie Suter,

Martin Proescholdt

и другие.

Psychiatry Research Case Reports, Год журнала: 2025, Номер unknown, С. 100252 - 100252

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
The Missing Piece? A Case for Microglia’s Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics DOI
Jared VanderZwaag, Torin Halvorson,

Kira Dolhan

и другие.

Neurochemical Research, Год журнала: 2022, Номер 48(4), С. 1129 - 1166

Опубликована: Ноя. 3, 2022

Язык: Английский

Процитировано

17
MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations DOI Creative Commons
Samuli Kangaslampi, Josjan Zijlmans

European Child & Adolescent Psychiatry, Год журнала: 2023, Номер unknown

Опубликована: Окт. 10, 2023

3,4-Methylenedioxymetamphetamine(MDMA)-assisted psychotherapy (MDMA-AP) is a proposed treatment for posttraumatic stress disorder (PTSD) that may be approved adults soon. PTSD also common among trauma-exposed adolescents, and current treatments leave much room improvement. We present rationale considering MDMA-AP treating adolescents. Evidence suggests as an adjunct to therapy, MDMA reduce avoidance enable trauma processing, strengthen therapeutic alliance, enhance extinction learning trauma-related reappraisal, hold potential beyond symptoms. Drawing on existing trauma-focused treatments, we suggest possible adaptations use with focusing (1) reinforcing motivation, (2) the development of strong (3) additional emotion behavior management techniques, (4) more directive exposure-based methods during sessions, (5) support concomitant challenges integrating benefits, (6) involving family in treatment. then discuss risks particular including physical psychological side effects, toxicity, misuse potential, ethical issues. argue holds adolescents suffering from PTSD. Instead off-label or extrapolating adult studies, clinical trials should carried out determine whether safe effective

Язык: Английский

Процитировано

9
Psychedelic Therapy: A Primer for Primary Care Clinicians—3,4-Methylenedioxy-methamphetamine (MDMA) DOI
Kenneth Shinozuka, Burton J. Tabaac,

Alejandro Arenas

и другие.

American Journal of Therapeutics, Год журнала: 2024, Номер 31(2), С. e141 - e154

Опубликована: Март 1, 2024

Background: After becoming notorious for its use as a party drug in the 1980s, 3,4-methylenedioxy-methampetamine (MDMA), also known by street names “molly” and “ecstasy,” has emerged powerful treatment post-traumatic stress disorder (PTSD). Areas of Uncertainty: There are extensive data about risk profile MDMA. However, literature is significantly biased. Animal models demonstrating neurotoxic or adverse effects used doses well beyond range that would be expected humans (up to 40 mg/kg rats compared with roughly 1–2 humans). Furthermore, human samples often comprise recreational users who took other substances addition MDMA, uncontrolled settings. Therapeutic Advances: Phase III clinical trials led Multidisciplinary Association Psychedelic Studies (MAPS) have shown MDMA-assisted psychotherapy an effect size d = 0.7–0.91, up 2–3 times higher than sizes existing antidepressant treatments. 67%–71% patients undergo no longer meet diagnostic criteria PTSD within 18 weeks. We describe promising applications treating alcohol disorder, social anxiety, psychiatric conditions. Limitations: Thus far, almost all on MDMA been sponsored single organization, MAPS. More work needed determine whether therapy more effective nonpharmacological treatments such cognitive behavioral therapy. Conclusions: suggest superior medications PTSD. Now MAPS officially requested Food Drug Administration approve PTSD, legal may become available soon 2024.

Язык: Английский

Процитировано

3